A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Barr, Paul M., Ma, Shuo, Zent, Clive S., Baran, Andrea M., Bui, Andrew, Meacham, Philip J, Morrison, Ashley, Holkovic, Kelsey, Liesveld, Jane L., Mulford, Deborah A, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Hill, Brian T.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma
Hill, Brian T., Jagadeesh, Deepa, Mejia Garcia, Alex V., Dean, Robert M., Koc, Omer N., Kalaycio, Matt, Boughan, Kirsten M, Cooper, Brenda W., Winter, Allison M., Ahmed, Wesam B., Pohlman, Brad, D'Andrea, Christopher, Holkovic, Kelsey, Morrison, Ashley, Caimi, Paolo, Smith, Mitchell
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article